Anticonvulsant activity of acute and chronic treatment with a-asarone from Acorus gramineus in seizure models

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 1, 2013, Pages 23-30

  Chen, Qi Xiong ^a   Miao, Jing Kun ^b   Li, Chun ^a   Li, Xiao Wen ^a   Wu, Xiao Mei ^b   Zhang, Xiao Ping ^c  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Chongqing Intl Science and Technology Cooperation Center for Child Development and Disorders   (China)

^c CHONGQING KEY LABORATORY OF PEDIATRICS   (China)

Author keywords

A asarone; Acorus gramineus; Animal model; Anticonvulsant activity; Seizure

Indexed keywords

ALPHA ASARONE; CARBAMAZEPINE; CLONAZEPAM; LITHIUM; PENTETRAZOLE; PILOCARPINE; VALPROIC ACID;

ACORUS; ACORUS GRAMINEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG STRUCTURE; ELECTRIC SHOCK; EPILEPTIC STATE; LATENT PERIOD; LD 50; MALE; MORTALITY; NONHUMAN; RAT; SEIZURE; TOXICITY TESTING;

ACORUS; ANIMALS; ANISOLES; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; LETHAL DOSE 50; MICE; PHYTOTHERAPY; RATS; RATS, WISTAR; SEIZURES;

EID: 84872699736     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00376     Document Type: Article

References (40)

1. Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain, 129, 18-35 (2006).
2. Granata T, Marchi N, Carlton E, Ghosh C, Gonzalez-Martinez J, Alexopoulos AV, Janigro D. Management of the patient with medically refractory epilepsy. Expert Rev. Neurother., 9, 1791-1802 (2009).
3. Dalkara S, Karakurt A. Recent progress in anticonvulsant drug research: strategies for anticonvulsant drug development and applications of antiepileptic drugs for non-epileptic central nervous system disorders. Curr. Top. Med. Chem., 12, 1033-1071 (2012).
4. Spinella M. Herbal medicines and epilepsy: the potential for benefit and adverse effects. Epilepsy Behav., 2, 524-532 (2001).
5. Liu GQ, Sun JN, He ZZ, Jiang Y. Spasmolytic actions of active principles of volatile of Acorus gramineus (Chinese). Acta Pharmacol. Sin., 4, 95-97 (1983).
6. Vohora SB, Shah SA, Dandiya PC. Central nervous system studies on an ethanol extract of Acorus calamus rhizomes. J. Ethnopharmacol., 28, 53-62 (1990).
7. Liao WP, Chen L, Yi YH, Sun WW, Gao MM, Su T, Yang SQ. Study of antiepileptic effect of extract from acorus tatarinowii schott. Epilepsia, Suppl. 1, S21-S24 (2005).
8. Liao JF, Huang SY, Jan YM, Yu LL, Chen CF. Central inhibitory effects of water extract of Acori graminei rhizoma in mice. J. Ethnopharmacol., 61, 185-193 (1998).
9. Nishiyama N, Zhou Y, Takashina K, Saito H. Effects of DX-9386, a traditional Chinese preparation, on passive and active avoidance performances in mice. Biol. Pharm. Bull., 17, 1472-1476 (1994).
10. Lee B, Choi Y, Kim H, Kim SY, Hahm DH, Lee HJ, Shim I. Protective effects of methanol extract of Acori graminei rhizoma and UNCARIAE RAMULUS et UNCUS on ischemia-induced neuronal death and cognitive impairments in the rat. Life Sci., 74, 435-450 (2003).
11. Du Z, Clery RA, Hammond CJ. Volatiles from leaves and rhizomes of fragrant Acorus spp. (Acoraceae). Chem. Biodivers., 5, 887-895 (2008).
12. 2 extraction-gas chromatography-mass spectrometry. J. Sep. Sci., 31, 714-720 (2008).
13. Limón ID, Mendieta L, Díaz A, Chamorro G, Espinosa B, Zenteno E, Guevara J. Neuroprotective effect of alpha-asarone on spatial memory and nitric oxide levels in rats injected with amyloid-β (25-35). Neurosci. Lett., 453, 98-103 (2009).
14. Zhang H, Han T, Yu CH, Rahman K, Qin LP, Peng C. Ameliorating effects of essential oil from Acori graminei rhizoma on learning and memory in aged rats and mice. J. Pharm. Pharmacol., 59, 301-309 (2007).
15. Cho J, Kim YH, Kong JY, Yang CH, Park CG. Protection of cultured rat cortical neurons from excitotoxicity by asarone, a major essential oil component in the rhizomes of Acorus gramineus. Life Sci., 71, 591-599 (2002).
16. Koo BS, Park KS, Ha JH, Park JH, Lim JC, Lee DU. Inhibitory effects of the fragrance inhalation of essential oil from Acorus gramineus on central nervous system. Biol. Pharm. Bull., 26, 978-982 (2003).
17. Pages N, Maurois P, Delplanque B, Bac P, Stables JP, Tamariz J, Chamorro G, Vamecq J. Activities of α-asarone in various animal seizure models and in biochemical assays might be essentially accounted for by antioxidant properties. Neurosci. Res., 68, 337-344 (2010).
18. Lorke D. A new approach to practical acute toxicity testing. Arch. Toxicol., 54, 275-287 (1983).
19. Tedeschi DH, Swinyard EA, Goodman LS. Effects of variations in stimulus intensity on maximal electroshock seizure pattern, recovery time, and anticonvulsant potency of phenobarbital in mice. J. Pharmacol. Exp. Ther., 116, 107-113 (1956).
20. White HS, Johnson M, Wolf HH, Kupferberg HJ. The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital. J. Neurol. Sci., 16, 73-77 (1995).
21. Eells JB, Clough RW, Browning RA, Jobe PC. Fos in locus coeruleus neurons following audiogenic seizure in the genetically epilepsyprone rat: comparison to electroshock and pentylenetetrazol seizure models. Neurosci. Lett., 233, 21-24 (1997).
22. Turski WA, Cavalheiro EA, Schwarz M, Czuczwar SJ, Kleinrok Z, Turski L. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study. Behav. Brain Res., 9, 315-335 (1983).
23. Honchar MP, Olney JW, Sherman WR. Systemic cholinergic agents induce seizures and brain damage in lithium-treated rats. Science, 220, 323-325 (1983).
24. Müller CJ, Bankstahl M, Gröticke I, Löscher W. Pilocarpine vs. lithium-pilocarpine for induction of status epilepticus in mice: development of spontaneous seizures, behavioral alterations and neuronal damage. Eur. J. Pharmacol., 619, 15-24 (2009).
25. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol., 32, 281-294 (1972).
26. Leite JP, Cavalheiro EA. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res., 20, 93-104 (1995).
27. Medina-Franco JL, Lopez-vallejo FL, Rodriguez-Morales S, Castillo R, Chamorro G, Tamariz J. Molecular docking of the highly hypolipidemic agent a-asarone with the catalytic portion of HMG-CoA reductase. Bioorg. Med. Chem. Lett., 4, 989-994 (2005).
28. Sharma JD, Dandiya PC, Baxter RM, Kandel SI. Pharmacodynamical effects of asarone and β-asarone. Nature, 192, 1299-1300 (1961).
29. Zanoli P, Avallone R, Baraldi M. Sedative and hypothermic effects induced by β-asarone, a main component of Acorus calamus. Phytother. Res., 12 (Suppl. 1), 114-116 (1998).
30. Dandiya PC, Menon MK. Effects of asarone and β-asarone on conditioned responses, fighting behaviour and convulsions. Br. Pharmacol. Chemother., 20, 436-442 (1963).
31. Hu JG, Gu J, Wang ZW. Central inhibitory effects of Acrous gramineus and its component in mice. Pharmacol. Clin. Chin. Mater. Med., 15, 19-21 (1999).
32. Löscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res., 8, 79-94 (1991).
33. White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia, Suppl. 1, S9-S17 (1997).
34. Toman JE, Swinyard EA. Some properties of experimental electroshock seizures. Proc. Am. Fed. Clin. Res., 2, 98-99 (1945).
35. Laffan RJ, Swinyard EA, Goodman LS. Stimulus intensity, maximal electroshock seizures, and potency of anticonvulsants in rats. Arch. Int. Pharmacodyn. Ther., 111, 60-69 (1957).
36. Löscher W, Hönack D, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res., 8, 171-189 (1991).
37. Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res., 2, 145-181 (1988).
38. Curia G, Longo D, Biagini G, Jones RS, Avoli M. The pilocarpine model of temporal lobe epilepsy. J. Neurosci. Methods, 172, 143-157 (2008).
39. André V, Dubé C, François J, Leroy C, Rigoulot MA, Roch C, Namer IJ, Nehlig A. Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia, Suppl. 5, S41-S47 (2007).
40. Furtado MA, Castro OW, Del Vecchio F, de Oliveira JA, Garcia-Cairasco N. Study of spontaneous recurrent seizures and morphological alterations after status epilepticus induced by intrahippocampal injection of pilocarpine. Epilepsy Behav., 20, 257-266 (2011).